

Financial Tear Sheet

Corporate Profile

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.

Recent Headlines

06/28/18

[Multi-Center Market Research Confirms Nasal Valve Collapse as a Contributor for Most Nasal Obstruction Sufferers](#)

06/19/18

[Entellus Medical announces publication of the 1-year results of a randomized controlled trial comparing balloon dilation with medical therapy for treatment of persistent Eustachian tube dysfunction](#)

05/31/18

[Entellus Medical Announces Multi-Center Clinical Study Publication Confirming Nasal Obstruction Symptom Improvement from LATERA](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
02/01/19	SC 13G
03/12/18	15-12B
03/08/18	SC 13D/A
03/07/18	SC 13D/A

Corporate Governance

[Robert S. White](#)

President and CEO

[Brent A. Moen](#)

CFO

[Michael H. Rosenthal](#)

Chief Operating Officer

[Donald Gonzales, M.D.](#)

Chief Medical Officer

[Thomas P. Williamson](#)

Vice President, Commercial Operations

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)